4.03
-0.05
(-1.23%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 3.98 - 4.09 |
| 52 week | 2.65 - 5.36 |
| Open | 4.04 |
| Vol / Avg. | 984,634.00/2.65M |
| Mkt cap | 464.06M |
| P/E | - |
| Div/yield | - |
| EPS | -1.06 |
| Shares | 115.15M |
| Beta | 0.06 |
| Inst. own | 74% |
Events
Jul 22, 2013
Q2 2013 Sequenom Earnings Release
May 16, 2013
Sequenom at Bank of America Merrill Lynch Health Care Conference
May 9, 2013
Q1 2013 Sequenom Earnings Conference Call
Apr 29, 2013
Q1 2013 Sequenom Earnings Release
Mar 18, 2013
Sequenom at Roth Conference
Mar 13, 2013
Sequenom at Barclays Healthcare Conference
Mar 7, 2013
Q4 2012 Sequenom Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -76.26% | -130.47% |
| Operating margin | -70.17% | -125.77% |
| EBITD margin | - | -113.37% |
| Return on average assets | -49.38% | -60.20% |
| Return on average equity | -334.47% | -168.16% |
| Employees | 594 | - |
| Carbon Disclosure Rating | - | - |
Address
3595 John Hopkins Court
SAN DIEGO, CA 92121-1331
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)
SAN DIEGO, CA 92121-1331
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Manufactures DNA detection and sequencing equipment. The Company's two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository. Sequenom provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine and agricultural applications.
Officers and directors
| Harry F. Hixson Jr., Ph.D. | Chairman of the Board, Chief Executive Officer | |
| William J. Welch | President, Chief Operating Officer | |
| Paul V. Maier | Chief Financial Officer | |
| Dirk van den Boom Ph.D. | Executive Vice President - Research and Development, Chief Technology Officer | |
| Ronald M. Lindsay Ph.D. | Executive Vice President - Strategic Planning, Director | |
| Bill Bowen | Senior Vice President, General Counsel, Secretary | |
| Michael Monko | Senior Vice President - Genetic Analysis | |
| Robin G. Weiner | Senior Vice President - Quality and Regulatory Affairs | |
| Charles R. Cantor Ph.D. | Chief Scientific Officer | |
| Carolyn D. Beaver | Vice President, Chief Accounting Officer |